Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE
Sponsor: Pfizer
Listed as NCT03313037, this PHASE2 trial focuses on Pneumococcal Infections and remains completed. Sponsored by Pfizer, it has been updated 13 times since 2017, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
-
May 2019 — Jan 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Sep 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2018 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .